Song Anna, Deshmukh Rashmi, Lin Haotian, Ang Marcus, Mehta Jodhbir S, Chodosh James, Said Dalia G, Dua Harminder S, Ting Darren S J
Newcastle University, Newcastle upon Tyne, United Kingdom.
Department of Ophthalmology, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, United Kingdom.
Front Med (Lausanne). 2021 Jul 7;8:707242. doi: 10.3389/fmed.2021.707242. eCollection 2021.
Post-keratoplasty infectious keratitis (PKIK) represents a unique clinical entity that often poses significant diagnostic and therapeutic challenges. It carries a high risk of serious complications such as graft rejection and failure, and less commonly endophthalmitis. Topical corticosteroids are often required to reduce the risk of graft rejection but their use in PKIK may act as a double-edged sword, particularly in fungal infection. The increased uptake in lamellar keratoplasty in the recent years has also led to complications such as graft-host interface infectious keratitis (IIK), which is particularly difficult to manage. The reported incidence of PKIK differs considerably across different countries, with a higher incidence observed in developing countries (9.2-11.9%) than developed countries (0.02-7.9%). Common risk factors for PKIK include the use of topical corticosteroids, suture-related problems, ocular surface diseases and previous corneal infection. PKIK after penetrating keratoplasty or (deep) anterior lamellar keratoplasty is most commonly caused by ocular surface commensals, particularly Gramme-positive bacteria, whereas PKIK after endothelial keratoplasty is usually caused by . Empirical broad-spectrum antimicrobial treatment is the mainstay of treatment for both PKIK, though surgical interventions are required in medically refractory cases (during the acute phase) and those affected by visually significant scarring (during the late phase). In this paper, we aim to provide a comprehensive overview on PKIK, encompassing the epidemiology, risk factors, causes, management and outcomes, and to propose a treatment algorithm for systematically managing this challenging condition.
角膜移植术后感染性角膜炎(PKIK)是一种独特的临床病症,常常带来重大的诊断和治疗挑战。它具有发生严重并发症的高风险,如移植排斥和失败,较少见的还有眼内炎。通常需要局部使用皮质类固醇来降低移植排斥的风险,但它们在PKIK中的使用可能是一把双刃剑,尤其是在真菌感染时。近年来板层角膜移植术的应用增加也导致了诸如移植-宿主界面感染性角膜炎(IIK)之类的并发症,这种并发症特别难以处理。不同国家报道的PKIK发病率差异很大,发展中国家(9.2 - 11.9%)的发病率高于发达国家(0.02 - 7.9%)。PKIK的常见风险因素包括局部使用皮质类固醇、缝线相关问题、眼表疾病和既往角膜感染。穿透性角膜移植术或(深层)前板层角膜移植术后的PKIK最常见由眼表共生菌引起,尤其是革兰氏阳性菌,而内皮角膜移植术后的PKIK通常由……引起。经验性广谱抗菌治疗是PKIK治疗的主要方法,不过对于药物治疗无效的病例(急性期)和受明显视觉瘢痕影响的病例(后期)需要进行手术干预。在本文中,我们旨在全面概述PKIK,涵盖流行病学、风险因素、病因、管理和结果,并提出一种治疗算法以系统地处理这种具有挑战性的病症。